Navigation Links
Hagens Berman Sobol Shapiro Investigating CellCyte
Date:1/9/2008

SEATTLE, Jan 9 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP (http://www.hbsslaw.com/cellcyte.htm) today announced it is investigating the business practices of CellCyte (OTC Bulletin Board: CCYG) for potential violations of securities laws.

The investigation comes after CellCyte's shares plunged 55 percent after news reports detailed alleged discrepancies in CellCyte CEO Gary Reys' educational and professional credentials.

CellCyte's stock dropped after the company made changes to its Web site concerning Reys' claims to have attended University of Washington and to be a certified public accountant. Media reports also call into question other claims made by Reys concerning his role in other business ventures.

According to published media reports, the changes were prompted by calls from Seattle media questioning the veracity of Reys' claims.

If you are an investor in CellCyte, have information concerning this investigation or if you have any questions concerning CellCyte's actions, please contact plaintiff's counsel at 206-623-7292 or e-mail the law firm at info@hbsslaw.com. You can view additional materials on this investigation at http://www.hbsslaw.com/cellcyte.htm.

Hagens Berman Sobol Shapiro, a law firm with offices in Seattle, San Francisco, Los Angeles, Boston, Chicago and Phoenix, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Hagens Berman Web site (http://www.hbsslaw.com) has more information about the firm.

Contact: Hagens Berman Sobol Shapiro LLP

206-623-7292

info@hbsslaw.com

http://www.hbsslaw.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
4. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
Breaking Biology News(10 mins):